A 2026 retrospective study in The Lancet found that postmenopausal women receiving tirzepatide alongside hormone therapy were more than four times as likely to achieve 30% weight loss compared to those on tirzepatide alone: 18% versus 4%
Since the first GLP-1 RA (exenatide twice daily) was approved in 2005 by U.S
If you're concerned about what the compounding changes mean for your weight loss treatment, our team can help you evaluate your options and create a plan that works for you
Sun et al., 2022 Cryo-EM Structural Determinants Sun and colleagues reported cryo-electron microscopy structures of tirzepatide in complex with both the GIP receptor and the GLP-1 receptor in the Proceedings of the National Academy of Sciences in 2022 [3]
Obesity, insulin resistance and type 2 diabetes associated to PCOS will enhance the risk of endometrial cancer in PCOS patients [21, 22]
The FDA reprinted the admission in its decision but then ignored it, Grossman said